Jong-Ho Hong
Chief Executive Officer en KUKJEON PHARMACEUTICAL CO., LTD .
Fortuna: 97 M $ al 31/03/2024
Perfil
Jong-Ho Hong is currently the Chief Executive Officer at Kukjeon Pharm Co., Ltd.
and the Chief Executive Officer & Director at Kukjeon Pharmaceutical Co., Ltd.
He has a graduate degree from Sogang University and an undergraduate degree from Sungkyunkwan University.
Participaciones conocidas en empresas públicas
| Empresa | Fecha | Número de acciones | Valoración | Fecha de valoración |
|---|---|---|---|---|
| 22/04/2024 | 21 373 361 ( 43.56% ) | 97 M $ | 31/03/2024 |
Cargos activos de Jong-Ho Hong
| Empresas | Cargo | Inicio |
|---|---|---|
| KUKJEON PHARMACEUTICAL CO., LTD | Chief Executive Officer | - |
Kukjeon Pharm Co., Ltd.
 Kukjeon Pharm Co., Ltd. Pharmaceuticals: MajorHealth Technology Kukjeon Pharm Co., Ltd. manufactures medicines and antibiotics. The firm’s products include celecoxib, choline alfoscerate, dibucaine, enoxolone, eperisone HCL, epinastine HCL, hinokitiol and nizatidine. The company was founded on July 26, 1995 and is headquartered in Anyang-si, South Korea. | Chief Executive Officer | - |
Formación de Jong-Ho Hong.
| Sogang University | Graduate Degree |
| Sungkyunkwan University | Undergraduate Degree |
Experiencias
Funciones ocupadas
Activas
Inactivas
Empresas cotizadas
Empresas privadas
Relaciones
Relaciones de 1er grado
Empresas vinculadas al 1er grado
Hombre
Mujer
Administradores
Ejecutivos
Empresas relacionadas
| Empresas privadas | 2 |
|---|---|
Kukjeon Pharm Co., Ltd.
Kukjeon Pharm Co., Ltd. Pharmaceuticals: MajorHealth Technology Kukjeon Pharm Co., Ltd. manufactures medicines and antibiotics. The firm’s products include celecoxib, choline alfoscerate, dibucaine, enoxolone, eperisone HCL, epinastine HCL, hinokitiol and nizatidine. The company was founded on July 26, 1995 and is headquartered in Anyang-si, South Korea. | Health Technology |
| Kukjeon Pharmaceutical Co., Ltd. |
- Bolsa de valores
- Insiders
- Jong-Ho Hong
